查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
罕見內分泌疾病治療的全球市場 - 全球產業分析、規模、份額、成長、趨勢、預測 (2031) - 按適應症、按藥物類型、按給藥方式、按分銷管道、按地區
市場調查報告書
商品編碼
1410592

罕見內分泌疾病治療的全球市場 - 全球產業分析、規模、份額、成長、趨勢、預測 (2031) - 按適應症、按藥物類型、按給藥方式、按分銷管道、按地區

Rare Endocrine Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:
出版日期: | 出版商: Fairfield Market Research | 英文 170 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

肥胖現在被認為是全球性的流行病，它不僅影響多囊性卵巢症候群、甲狀腺功能減退症等常見疾病，也影響下視丘疾病、庫欣氏症候群等罕見疾病，與多種內分泌疾病密切相關，包括：

肥胖發生的機制因特定的內分泌疾病而異。 在罕見的內分泌疾病中，生長激素和甲狀腺功能的相互作用至關重要，並且通常與脂肪生成和脂肪細胞分化的增強有關。

世界各地的研究人員正在積極評估罕見內分泌疾病的治療策略，特別關注超重患者。 例如，紐卡斯爾大學的科學家熱衷於評估肥胖發展的自然史，同時考慮各種病因因素。

儘管尚未實現全面評估，但研究人員正在努力擴大評估流程，排除常見的內分泌原因，為選擇適當的治療方法鋪路。

內分泌疾病的罕見性給研究人員和臨床醫生收集足夠的患者數據以進行穩健的臨床試驗帶來了挑戰。 內分泌基因組虛擬實驗室 (endoVL) 透過提供對分析工具和廣泛數據集的安全線上存取來應對這一挑戰，從而實現協作研究以推進罕見內分泌疾病的診斷和治療。

endoVL 登記了超過 8,500 例腎上腺腫瘤病例，使研究人員能夠利用大型隊列進行具有統計學意義的分析。 目前有超過25項endoVL大型臨床試驗正在進行中，涉及世界各地的研究團隊。 這種合作研究工作具有巨大的潛力，可以釋放全球罕見內分泌疾病治療市場的新增長機會。

罕見的內分泌疾病通常會出現多重器官症狀，由於獨特的病理生理障礙，首先出現在眼睛中。 認識罕見內分泌疾病的眼部表現對於及時診斷、治療和預防顯著的發病率和死亡率至關重要。

生物技術和製藥公司與醫學研究人員一起，預計將重點解決罕見內分泌疾病的眼科表現，並加速這一重要領域的治療開發和創新。

本報告調查了全球罕見內分泌疾病治療市場，並提供了市場概況，以及按適應症、藥物類型、給藥方式、分銷渠道、地區和進入市場的公司劃分的趨勢。提供了競爭資訊趨勢等

目錄

第 1 章執行摘要

第二章市場概述

  • 市場定義與細分
  • 市場動態
  • 價值鏈分析
  • 波特五力分析
  • 新冠肺炎 (COVID-19) 影響分析
  • 烏克蘭和俄羅斯之間衝突的影響
  • 經濟概況
  • 杵分析

第三章2018-2031年全球罕見內分泌疾病治療市場展望

  • 2018-2031 年全球罕見內分泌疾病治療市場前景（依適應症、價值（百萬美元）、數量（噸））
  • 2018-2031 年全球罕見內分泌疾病治療市場前景，以藥物類型、價值（百萬美元）、數量（噸）劃分
  • 2018-2031 年全球罕見內分泌疾病治療市場前景（依給藥方式、價值（百萬美元）、數量（噸））
  • 2018-2031 年全球罕見內分泌疾病治療市場前景（按分銷管道劃分）、價值（百萬美元）、數量（噸）
  • 2018-2031 年全球罕見內分泌疾病治療市場前景（按地區、價值（百萬美元）、數量（噸））

第4章2018-2031年北美罕見內分泌疾病治療市場前景

第五章歐洲罕見內分泌疾病治療市場展望，2018-2031

第六章2018-2031年亞太地區罕見內分泌疾病治療市場前景

第 7 章 2018-2031 年拉丁美洲罕見內分泌疾病治療市場展望

第8章中東及非洲罕見內分泌疾病治療市場前景，2018-2031

第九章競爭態勢

  • 依給藥模式和藥物類型劃分的熱圖
  • 按製造商和藥物類型劃分的熱圖
  • 2023 年公司市佔率分析
  • 競爭力儀表板
  • 公司簡介
    • Novartis
    • Ipsen
    • Pfizer, Inc
    • Teva
    • EMD serono
    • Novo Nordisk
    • Eli Lilly
    • Shire
    • Amgen, Inc
    • Corcept Therapeutics
    • Novelion Therapeutics

第 10 章附錄

簡介目錄

The global rare endocrine disease treatment market, intricately linked with obesity and endocrine disorders, is poised for moderate growth in the forecast period from 2024 to 2031, according to a recent research study conducted by Fairfield Market Research.

Endocrine Diseases and the Obesity Connection

Obesity, now considered a global pandemic, has been closely associated with a range of endocrine diseases, including both common conditions like polycystic ovarian syndrome and hypothyroidism, as well as rare ailments such as hypothalamic disorders and Cushing's syndrome.

The mechanisms underlying obesity development vary depending on the specific endocrine disorder. In the case of rare endocrine diseases, interactions with growth hormones and thyroid functions are pivotal, often coupled with increased adipogenesis and adipocyte differentiation.

Researchers Focus on Treatment Evaluation

Researchers worldwide are actively engaged in evaluating treatment strategies for rare endocrine diseases, with a particular emphasis on overweight patients. For instance, scientists at the University of Newcastle are diligently assessing the natural history of obesity development, taking into account the various etiological factors at play.

While a comprehensive evaluation has not yet been achieved, researchers are conducting laboratory tests and physical examinations to expand the evaluation process, ruling out common endocrine causes and paving the way for appropriate treatment selection.

Research Collaboration Revolutionizes Rare Endocrine Disease Treatment

The rarity of endocrine diseases poses challenges for researchers and clinicians in gathering sufficient patient data for robust clinical trials. The Endocrine Genomics Virtual Laboratory (endoVL) addresses this challenge by providing secure online access to analytical tools and extensive datasets, enabling collaborative efforts to advance the diagnosis and treatment of rare endocrine diseases.

With more than 8,500 registered cases of adrenal tumors, endoVL empowers researchers to leverage large cohorts for statistically significant analyses. Currently, more than 25 large-scale clinical trials are underway within endoVL, engaging research groups from around the world. This collaborative research effort holds immense potential to unlock new growth opportunities in the global rare endocrine disease treatment market.

Innovations in Ophthalmic Manifestations

Rare endocrine disorders often manifest multi-organ symptoms, initially appearing in the eyes through distinct pathophysiological disturbances. Recognizing ophthalmic manifestations of rare endocrine diseases is crucial for swift diagnosis, treatment, and the prevention of significant morbidity and mortality.

Biotechnology and pharmaceutical companies, alongside medical researchers, are expected to focus on addressing ophthalmic manifestations of rare endocrine diseases, fostering treatment developments and innovations in this critical area.

Key Players in Rare Endocrine Disease Treatment

Prominent companies contributing to advancements in rare endocrine disease treatment, as identified by PMR's report, include Novartis, Ipsen, Pfizer, Inc., Teva, EMD Serono, Novo Nordisk, Eli Lilly, Shire, Amgen, Inc., Corcept Therapeutics, and Novelion Therapeutics.

Notably, Spruce Biosciences, a clinical-stage biotechnology firm, recently received FDA orphan drug designation for its SPR001, a potential treatment for congenital adrenal hyperplasia (CAH), a rare endocrine disease.

Rare Endocrine Disease Treatment Market Segmentation

Indication

  • Acromegaly
  • Central Diabetes Insipidus
  • Ahumada-Del Castillo Syndrome
  • Hypoparathyroidism
  • Other Indications

Drug Type

  • Biologics
  • Organic Compounds

Mode of Administration

  • Injectables
  • Oral
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North Americ
  • Latin America
  • Europe
  • Japan
  • APEJ
  • MEA

Table of Contents

1. Executive Summary

  • 1.1. Global Rare Endocrine Disease Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value and Volume, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

  • 3.1. Global Rare Endocrine Disease Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Acromegaly
      • 3.1.1.2. Central Diabetes Insipidus
      • 3.1.1.3. Ahumada-Del Castillo Syndrome
      • 3.1.1.4. Hypoparathyroidism
      • 3.1.1.5. Other Indications
  • 3.2. Global Rare Endocrine Disease Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Biologics
      • 3.2.1.2. Organic Compounds
  • 3.3. Global Rare Endocrine Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Injectables
      • 3.3.1.2. Oral
      • 3.3.1.3. Others
  • 3.4. Global Rare Endocrine Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. Hospital Pharmacies
      • 3.4.1.2. Retail Pharmacies
      • 3.4.1.3. Online Pharmacies
  • 3.5. Global Rare Endocrine Disease Treatment Market Outlook, by Region, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 3.5.1. Key Highlights
      • 3.5.1.1. North America
      • 3.5.1.2. Europe
      • 3.5.1.3. Asia Pacific
      • 3.5.1.4. Latin America
      • 3.5.1.5. Middle East & Africa

4. North America Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

  • 4.1. North America Rare Endocrine Disease Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Acromegaly
      • 4.1.1.2. Central Diabetes Insipidus
      • 4.1.1.3. Ahumada-Del Castillo Syndrome
      • 4.1.1.4. Hypoparathyroidism
      • 4.1.1.5. Other Indications
  • 4.2. North America Rare Endocrine Disease Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Biologics
      • 4.2.1.2. Organic Compounds
  • 4.3. North America Rare Endocrine Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Injectables
      • 4.3.1.2. Oral
      • 4.3.1.3. Others
  • 4.4. North America Rare Endocrine Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. Hospital Pharmacies
      • 4.4.1.2. Retail Pharmacies
      • 4.4.1.3. Online Pharmacies
  • 4.5. North America Rare Endocrine Disease Treatment Market Outlook, by Country, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 4.5.1. Key Highlights
      • 4.5.1.1. U.S. Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 4.5.1.2. U.S. Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 4.5.1.3. U.S. Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 4.5.1.4. U.S. Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 4.5.1.5. Canada Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 4.5.1.6. Canada Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 4.5.1.7. Canada Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 4.5.1.8. Canada Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

  • 5.1. Europe Rare Endocrine Disease Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Acromegaly
      • 5.1.1.2. Central Diabetes Insipidus
      • 5.1.1.3. Ahumada-Del Castillo Syndrome
      • 5.1.1.4. Hypoparathyroidism
      • 5.1.1.5. Other Indications
  • 5.2. Europe Rare Endocrine Disease Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Biologics
      • 5.2.1.2. Organic Compounds
  • 5.3. Europe Rare Endocrine Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Injectables
      • 5.3.1.2. Oral
      • 5.3.1.3. Others
  • 5.4. Europe Rare Endocrine Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Hospital Pharmacies
      • 5.4.1.2. Retail Pharmacies
      • 5.4.1.3. Online Pharmacies
  • 5.5. Europe Rare Endocrine Disease Treatment Market Outlook, by Country, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 5.5.1. Key Highlights
      • 5.5.1.1. Germany Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.2. Germany Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.3. Germany Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.4. Germany Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.5. U.K. Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.6. U.K. Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.7. U.K. Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.8. U.K. Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.9. France Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.10. France Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.11. France Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.12. France Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.13. Italy Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.14. Italy Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.15. Italy Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.16. Italy Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.17. Turkey Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.18. Turkey Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.19. Turkey Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.20. Turkey Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.21. Russia Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.22. Russia Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.23. Russia Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.24. Russia Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.25. Rest of Europe Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.26. Rest of Europe Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.27. Rest of Europe Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.28. Rest of Europe Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Rare Endocrine Disease Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Acromegaly
      • 6.1.1.2. Central Diabetes Insipidus
      • 6.1.1.3. Ahumada-Del Castillo Syndrome
      • 6.1.1.4. Hypoparathyroidism
      • 6.1.1.5. Other Indications
  • 6.2. Asia Pacific Rare Endocrine Disease Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Biologics
      • 6.2.1.2. Organic Compounds
  • 6.3. Asia Pacific Rare Endocrine Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Injectables
      • 6.3.1.2. Oral
      • 6.3.1.3. Others
  • 6.4. Asia Pacific Rare Endocrine Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. Hospital Pharmacies
      • 6.4.1.2. Retail Pharmacies
      • 6.4.1.3. Online Pharmacies
  • 6.5. Asia Pacific Rare Endocrine Disease Treatment Market Outlook, by Country, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 6.5.1. Key Highlights
      • 6.5.1.1. China Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.2. China Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.3. China Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.4. China Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.5. Japan Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.6. Japan Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.7. Japan Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.8. Japan Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.9. South Korea Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.10. South Korea Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.11. South Korea Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.12. South Korea Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.13. India Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.14. India Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.15. India Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.16. India Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.17. Southeast Asia Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.18. Southeast Asia Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.19. Southeast Asia Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.20. Southeast Asia Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.21. Rest of Asia Pacific Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.22. Rest of Asia Pacific Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.23. Rest of Asia Pacific Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.24. Rest of Asia Pacific Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

  • 7.1. Latin America Rare Endocrine Disease Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Acromegaly
      • 7.1.1.2. Central Diabetes Insipidus
      • 7.1.1.3. Ahumada-Del Castillo Syndrome
      • 7.1.1.4. Hypoparathyroidism
      • 7.1.1.5. Other Indications
  • 7.2. Latin America Rare Endocrine Disease Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Biologics
      • 7.2.1.2. Organic Compounds
  • 7.3. Latin America Rare Endocrine Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Injectables
      • 7.3.1.2. Oral
      • 7.3.1.3. Others
  • 7.4. Latin America Rare Endocrine Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Hospital Pharmacies
      • 7.4.1.2. Retail Pharmacies
      • 7.4.1.3. Online Pharmacies
  • 7.5. Latin America Rare Endocrine Disease Treatment Market Outlook, by Country, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 7.5.1. Key Highlights
      • 7.5.1.1. Brazil Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.2. Brazil Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.3. Brazil Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.4. Brazil Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.5. Mexico Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.6. Mexico Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.7. Mexico Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.8. Mexico Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.9. Argentina Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.10. Argentina Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.11. Argentina Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.12. Argentina Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.13. Rest of Latin America Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.14. Rest of Latin America Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.15. Rest of Latin America Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.16. Rest of Latin America Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Rare Endocrine Disease Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Acromegaly
      • 8.1.1.2. Central Diabetes Insipidus
      • 8.1.1.3. Ahumada-Del Castillo Syndrome
      • 8.1.1.4. Hypoparathyroidism
      • 8.1.1.5. Other Indications
  • 8.2. Middle East & Africa Rare Endocrine Disease Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Biologics
      • 8.2.1.2. Organic Compounds
  • 8.3. Middle East & Africa Rare Endocrine Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Injectables
      • 8.3.1.2. Oral
      • 8.3.1.3. Others
  • 8.4. Middle East & Africa Rare Endocrine Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. Hospital Pharmacies
      • 8.4.1.2. Retail Pharmacies
      • 8.4.1.3. Online Pharmacies
  • 8.5. Middle East & Africa Rare Endocrine Disease Treatment Market Outlook, by Country, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 8.5.1. Key Highlights
      • 8.5.1.1. GCC Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.2. GCC Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.3. GCC Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.4. GCC Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.5. South Africa Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.6. South Africa Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.7. South Africa Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.8. South Africa Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.9. Egypt Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.10. Egypt Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.11. Egypt Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.12. Egypt Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.13. Nigeria Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.14. Nigeria Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.15. Nigeria Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.16. Nigeria Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.17. Rest of Middle East & Africa Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.18. Rest of Middle East & Africa Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.19. Rest of Middle East & Africa Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.20. Rest of Middle East & Africa Rare Endocrine Disease Treatment Market by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. by Mode of Administration vs by Drug Type Heatmap
  • 9.2. Manufacturer vs by Drug Type Heatmap
  • 9.3. Company Market Share Analysis, 2023
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Novartis
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Product Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Ipsen
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Product Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. Pfizer, Inc
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Product Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. Teva
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Product Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. EMD serono
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Product Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. Novo Nordisk
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Product Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. Eli Lilly
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Product Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. Shire
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Product Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. Amgen, Inc
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Product Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development
    • 9.5.10. Corcept Therapeutics
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Product Portfolio
      • 9.5.10.3. Financial Overview
      • 9.5.10.4. Business Strategies and Development
    • 9.5.11. Novelion Therapeutics
      • 9.5.11.1. Company Overview
      • 9.5.11.2. Product Portfolio
      • 9.5.11.3. Financial Overview
      • 9.5.11.4. Business Strategies and Development

9.5.12.

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations